Redmond Asset Management’s BriaCell Therapeutics Corp Warrant BCTXW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-75,000
| Closed | -$2.35K | – | 199 |
|
|
2025
Q4 | $2.35K | Hold |
75,000
| – | – | ﹤0.01% | 197 |
|
|
2025
Q3 | $2.36K | Hold |
75,000
| – | – | ﹤0.01% | 198 |
|
|
2025
Q2 | $5.65K | Hold |
75,000
| – | – | ﹤0.01% | 209 |
|
|
2025
Q1 | $7.65K | Hold |
75,000
| – | – | ﹤0.01% | 205 |
|
|
2024
Q4 | $18K | Hold |
75,000
| – | – | ﹤0.01% | 203 |
|
|
2024
Q3 | $30.8K | Hold |
75,000
| – | – | 0.01% | 152 |
|
|
2024
Q2 | $17.2K | Hold |
75,000
| – | – | 0.01% | 155 |
|
|
2024
Q1 | $97.5K | Hold |
75,000
| – | – | 0.03% | 149 |
|
|
2023
Q4 | $188K | Hold |
75,000
| – | – | 0.06% | 153 |
|
|
2023
Q3 | $180K | Hold |
75,000
| – | – | 0.06% | 155 |
|
|
2023
Q2 | $188K | Hold |
75,000
| – | – | 0.06% | 154 |
|
|
2023
Q1 | $213K | Hold |
75,000
| – | – | 0.07% | 157 |
|
|
2022
Q4 | $144K | Hold |
75,000
| – | – | 0.05% | 165 |
|
|
2022
Q3 | $215K | Hold |
75,000
| – | – | 0.08% | 159 |
|
|
2022
Q2 | $190K | Hold |
75,000
| – | – | 0.07% | 174 |
|
|
2022
Q1 | $390K | Hold |
75,000
| – | – | 0.12% | 161 |
|
|
2021
Q4 | $341K | Hold |
75,000
| – | – | 0.1% | 172 |
|
|
2021
Q3 | $363K | Hold |
75,000
| – | – | 0.11% | 162 |
|
|
2021
Q2 | $135K | Hold |
75,000
| – | – | 0.04% | 187 |
|
|
2021
Q1 | $80K | Buy |
+75,000
| New | +$73.4K | 0.02% | 188 |
|
Redmond Asset Management's BCTXW Position: Q1 2026 in Review
Redmond Asset Management sold out of BriaCell Therapeutics Corp Warrant (BCTXW) in Q1 2026, closing a stake of 75,000 shares — an estimated $2.35K sold.
Redmond Asset Management first reported a position in BCTXW in Q1 2021 and held it in 20 quarters. The position peaked at $390K in Q1 2022. 0 funds tracked by Wall St. Rank hold BCTXW as of Q1 2026.
- Redmond Asset Management reported no remaining BriaCell Therapeutics Corp Warrant position as of Q1 2026 after selling out during the quarter.
- Redmond Asset Management sold 75,000 BriaCell Therapeutics Corp Warrant shares in Q1 2026, an estimated $2.35K.
- Redmond Asset Management first reported a position in BriaCell Therapeutics Corp Warrant in Q1 2021 and held it in 20 quarters.
- Redmond Asset Management's BriaCell Therapeutics Corp Warrant position peaked at $390K in Q1 2022.
- 0 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q1 2026.
Based on Redmond Asset Management's 13F filing for Q1 2026, filed 6 May 2026.